Skip to content Skip to main navigation Report an accessibility issue

Paul Dalhaimer

Paul Dalhaimer.

Paul Dalhaimer

Associate Professor


Contact Information

Paul Dalhaimer.

Group Website

Education

  • Post-doctoral Fellow, Yale University
    Gene targeting and purification of Arp2/3 complex in fission yeast; Molecular dynamics simulations of actin and Arp2/3 complex; Reconstitution of actin branches at an interface.
  • PhD, University of Pennsylvania
    Drug delivery vehicles; Statistical Mechanics of actin-spectrin networks.
  • BS Chemical Engineering; University of Pennsylvania

Biography

Paul Dalhaimer.

Paul Dalhaimer was educated in Chemical and Biomolecular Engineering at the University of Pennsylvania (BS and PhD) and was a Post-Doctoral Fellow in Cellular, Developmental, and Molecular Biology at Yale University where he was a recipient of a Ruth Kirschstein NRSA fellowship. He joined the faculty of Chemical and Biomolecular Engineering at the University of Tennessee in August of 2009. His laboratory has received funding from the American Heart Association and the National Institutes of Health. He has also worked at Kieffer & Co. (1998–1999) and Dow Jones (2000).

Awards and Recognitions

2005-2008 Ruth Kirschstein NRSA Postdoctoral-Fellow

Professional Service

Member

  • AIChE (1998–present)
  • Biomedical Engineering Society (2009–present)

Ad Hoc Grant Reviewer

  • Board of Reviewing Editors – Scientific Reports
  • American Heart Association – Molecular Signaling II (2013-2016; 2018-present)
  • NIH – BST AREA Bioengineering Study Section (2017)
  • NIH – NCI Clinical Translation R21 and Omnibus R03 (10/17/2018, 06/12/2019)
  • American Heart Association – Cellular Transport and Metabolism (2019-present)

Research

Paul Dalhaimer.

Our laboratory is focused on how mammals respond to soft nanoparticles that are used for general chemotherapy. This is a crucial aspect of nanomedicine. We are particularly interested in how metabolic imbalances such as obesity affect this process. The complications of obesity cause many side effects including varying lipoprotein levels and increased fattiness of the liver. We probe the way that these issues affect the pharmacokinetics and toxicity of nanoparticles that are under development and are also being used in the clinic. We aim at providing predictive, comprehensive models of nanoparticle efficacy in patients. We use a combination of genetics, proteomics, and live-cell microscopy to make advances in this topic.

Publications

  • Obesity and inflammation influence pharmacokinetic profiles of PEG-based nanoparticles. Mitch Raith, Nicole Nguyen, Sarah J. Kauffman, Namgoo Kang, Jimmy Mays, and Paul Dalhaimer. Journal of Controlled Release 355, 434-445 (2023) DOI: 10.1016/j.jconrel.2023.02.007

  • Interactions of Apolipoproteins with lipid-based nanoparticles. Paul Dalhaimer, Brice Florey, and Sami Isaac. A.C.S. Nano 17, 837-842 (2023) DOI: https://doi.org/10.1021/acsnano.2c10790

  • Tetra-primer amplification-refractory system (ARMS) – PCR for genotyping mouse leptin gene mutation. Jiangang Chen, Xinyun Xu, Paul Dalhaimer, and Ling Zhao. Animals 5, 2680 (2022). DOI: 10.3390/ani12192680

  • All-atom molecular dynamics simulations of poly-ethylene-glycol (PEG) and LIMP-2 reveal that PEG penetrates deep into the proposed cholesterol-transport tunnel. Paul Dalhaimer and Kate Blankenship. A.C.S. Omega 7, 15728-15738 (2022). DOI: https://doi.org/10.1021/acsomega.2c00667

  • Autophagy in cancer chemotherapy drug resistance. Monireh Asoudeh and Paul Dalhaimer. Scientific Letters 1, 4 (2022) DOI: https://doi.org/10.48797/sl.2022.10

  • Raith M, Kauffman SJ, Asoudeh M, Buczek JA, Kang NG, Mays JW, Dalhaimer P. Elongated PEO-based nanoparticles bind the high-density lipoprotein (HDL) receptor scavenger receptor class B I (SR-BI). J Control Release. 2021 Aug 3;337:448-457. DOI: 10.1016/j.jconrel.2021.07.045. Epub ahead of print. PMID: 34352314.
  • Dalhaimer, P., Raith, M., Kauffman, S., & Riley, D. (2020). PEGylated micelles interact directly with the major HDL receptor SR-B1 as a function of aspect ratio and are internalized into SR-B1-expressing cells. Poster session presented at the meeting of  Biomedical Engineering Society Annual Meeting.
  • Anozie, U. C., Quigley, K. J., Prescott, A., Abel, S. M., & Dalhaimer, P. (2020). Equilibrium binding of isolated and in-plasma high-density lipoproteins (HDLs) to polystyrene nanoparticles. Journal of Nanoparticle Research, 22(8). DOI:10.1007/s11051-020-04953-0
  • Dalhaimer, P., & Raith, M. (2019). The Effects of Scavenger Receptor Class B Type 1 on the Uptake of Both Hard and Soft Nanoparticles. Poster session presented at the meeting of  American Institute for Chemical Engineers.
  • Raith, M., & Dalhaimer, P. (2019). Modulating Lipid Droplet Breakdown in Mammalian Cells through a Split Mediated Interaction. Poster session presented at the meeting of  American Institute for Chemical Engineers.
  • Dalhaimer, P. (2019). The Effects of the Scavenger Receptor Class B Type I (SR-BI)  on the Uptake of Hard and Soft Nanoparticles. Poster session presented at the meeting of  Biomedical Engineering Society.
  • Dalhaimer, P., & Raith, M. (2019). Poly-ethylene-oxide (PEO)-based nanoparticles interact directly with the major HDL receptor, SR-BI. Poster session presented at the meeting of  South Eastern Lipid Research Conference.
  • Dalhaimer, P. (2019). Lipid Droplets in Disease. CELLS, 8(9), 3 pages. DOI:10.3390/cells8090974
  • Dalhaimer, P. (2018). The implications of competitive adsorption on lipoprotein-nanoparticle biodistribution. Poster session presented at the meeting of AIChE.
  • Anozie, U. C., & Dalhaimer, P. (2017). Molecular links among non-biodegradable nanoparticles, reactive oxygen species, and autophagy. Advanced Drug Delivery Reviews, 122, 65-73. DOI:10.1016/j.addr.2017.01.001
  • Dalhaimer, P. (2017). Influence of competitive adsorption on lipoprotein-nanoparticle kinetics. Poster session presented at the meeting of NanoDDS.
  • Meyers, A., Weiskittel, T. M., & Dalhaimer, P. (2017). Lipid Droplets: Formation to Breakdown. Lipids, 52(6), 465-475. doi:10.1007/s11745-017-4263-0
  • Dalhaimer, P. M., & Meyers, A. (2017). Signaling pathways for lipid droplet formation. Journal of Cell Signaling, 2(127), 127. Retrieved from https://www.omicsonline.org/
  • Meyers, A., Chourey, K., Weiskittel, T. M., Pfiffner, S., Dunlap, J. R., Hettich, R. L., & Dalhaimer, P. (2017). The protein and neutral lipid composition of lipid droplets isolated from the fission yeast, Schizosaccharomyces pombe. Journal of Microbiology, 55(2), 112-122. doi:10.1007/s12275-017-6205-1
  • Meyers, A., & Dalhaimer, P. (n.d.). Signaling Pathways for Triacylglycerol Lipid Droplet Formation. Journal of Cell Signaling, 02(02). DOI:10.4172/2576-1471.1000147